Progress Against Pancreatic Cancer, Part One

Key Takeaways

• Daraxonrasib doubled median overall survival in metastatic PDAC (13.2 vs 6.7 months)
• Drug stabilizes RAS–cyclophilin A complex, acting as molecular glue
• Patients reported severe skin bleeding and impaired wound healing
• RAS‑targeted therapies have been limited; this result revives hope for RAS‑addicted tumors
• If approved, daraxonrasib could be first RAS‑directed drug improving pancreatic survival

Pulse Analysis

Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, with five‑year survival under 10 percent and most patients diagnosed at an advanced stage. The disease’s biology is heavily driven by mutant RAS signaling, yet the RAS protein has eluded direct pharmacologic inhibition for decades, earning a reputation as "undruggable." Recent advances in covalent chemistry and protein‑protein interface targeting have opened a narrow path, but only a handful of mutant‑specific inhibitors have reached the clinic, and they address rare G12C alterations not prevalent in pancreatic tumors.

Daraxonrasib, Revolution Medicines’ latest candidate, takes a different approach by acting as a molecular glue that bridges RAS isoforms to cyclophilin A, creating a new binding pocket that locks the oncogenic protein in an inactive conformation. In a phase II cohort presented at AACR, patients receiving the drug experienced a median overall survival of 13.2 months—more than double the 6.7‑month benchmark for standard chemotherapy—while tumor volumes shrank by roughly 75 percent. The efficacy signal is striking, but safety signals are notable; participants reported extensive skin bleeding and delayed wound healing, underscoring the need for careful patient selection and supportive care protocols.

If regulatory approval follows, daraxonrasib could become the first RAS‑directed therapy to demonstrate a clear survival advantage in pancreatic cancer, opening a lucrative market estimated at several billion dollars annually in the United States alone. Its success may also catalyze broader investment in molecular‑glue platforms, encouraging biotech firms to revisit other “undruggable” targets. Clinicians will weigh the dramatic efficacy against the toxicity profile, while payers will scrutinize cost‑effectiveness in a disease area with few effective options. The drug’s trajectory will likely influence the strategic direction of oncology pipelines for years to come.